ARCAGY/ GINECO GROUP

Quick facts

Phase 3 pipeline

• atezolizumab + avastin + platinum-based chemotherapy · Oncology
  This combination uses an immune checkpoint inhibitor to block PD-L1, an anti-angiogenic monoclonal antibody to inhibit VEGF-mediated tumor blood vessel formation, and platinum-based chemotherapy to directly damage tumor DNA.
• Paraplatin · Oncology
• placebo + avastin + platinum-based chemotherapy · Oncology
  This combination uses platinum-based chemotherapy to damage cancer cell DNA while bevacizumab (Avastin) blocks tumor blood vessel formation, with placebo as a control arm.

Phase 2 pipeline

• Chemotherapy - Bevacizumab · Oncology
  Inhibits vascular endothelial growth factor A (VEGF-A)
• Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab
• Yondelis®-Caelyx®

Phase 1 pipeline

• carboplatin and liposomal doxorubicin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ARCAGY/ GINECO GROUP portfolio CI brief
• ARCAGY/ GINECO GROUP pipeline updates RSS